Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BU98008, a highly selective imidazoline(1)-receptor ligand.

E S J Robinson1, R E Price, D J Nutt

  • 1Psychopharmacology Unit, School of Medical Sciences, Bristol BS8 1TD, UK.

Annals of the New York Academy of Sciences
|March 19, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Human brain changes after first psilocybin use.

Nature communications·2026
Same author

Serotonergic psychedelics for depression: A comprehensive overview.

International review of neurobiology·2025
Same author

Suicidal Ideation in Medicinal Cannabis Patients: A 12-Month Prospective Study.

Archives of suicide research : official journal of the International Academy for Suicide Research·2024
Same author

Psilocybin and Other Classic Psychedelics in Depression.

Current topics in behavioral neurosciences·2023
Same author

Canalization and plasticity in psychopathology.

Neuropharmacology·2022
Same author

Incidence of hyperoxia in trauma patients receiving pre-hospital emergency anaesthesia: results of a 5-year retrospective analysis.

Scandinavian journal of trauma, resuscitation and emergency medicine·2021

The novel compound BU98008, an isoquinoline derivative, shows high affinity for the I(1) receptor. Initial studies suggest it may act as an I(1) receptor antagonist, but further central administration studies are needed.

Area of Science:

  • Pharmacology
  • Medicinal Chemistry
  • Neuroscience

Background:

  • The imidazoline I(1) receptor is a potential target for cardiovascular regulation.
  • Novel ligands are needed to selectively target I(1) receptors for therapeutic development.

Purpose of the Study:

  • To characterize the binding profile and in vivo effects of BU98008, a novel isoquinoline derivative.
  • To evaluate BU98008's potential as an I(1) receptor antagonist.

Main Methods:

  • Radioligand binding assays were performed using rat kidney and brain membranes.
  • In vivo studies assessed the effect of peripheral BU98008 administration on blood pressure in rats.

Main Results:

  • BU98008 exhibited high affinity for the I(1) receptor in rat kidney membranes.

Related Experiment Videos

  • The compound showed low affinity for I(2) binding sites and alpha(2)-adrenoceptors.
  • Peripheral administration of BU98008 did not alter blood pressure.

    • Conclusions:

    • BU98008 is a selective ligand for the I(1) receptor.
    • Preliminary data suggest BU98008 may function as an I(1) receptor antagonist.
    • Further investigation involving central administration is required to fully assess its potential hypotensive effects.